Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials

Stefanini, GiulioGiulioStefaniniByrne, Robert ARobert AByrneSerruys, Patrick WPatrick WSerruysde Waha, AntoinetteAntoinettede WahaMeier, BernhardBernhardMeierMassberg, SteffenSteffenMassbergJüni, PeterPeterJüniSchömig, AlbertAlbertSchömigWindecker, StephanStephanWindeckerKastrati, AdnanAdnanKastrati2024-10-112024-10-112012https://boris-portal.unibe.ch/handle/20.500.12422/77822The efficacy of durable polymer drug-eluting stents (DES) is delivered at the expense of delayed healing of the stented vessel. Biodegradable polymer DES aim to avoid this shortcoming and may potentially improve long-term clinical outcomes, with benefit expected to accrue over time. We sought to compare long-term outcomes in patients treated with biodegradable polymer DES vs. durable polymer sirolimus-eluting stents (SES).en600 - Technology::610 - Medicine & healthBiodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trialsarticle10.7892/boris.73672244780500030419440001510.1093/eurheartj/ehs086